Proteins from Mycobacterium tuberculosis

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 67: Line 67:
Tuberculosis continues to be a global health threat. Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis treatment. The emergence of strains resistant to pyrazinamide represents an important public health problem, as both first- and second-line treatment regimens include pyrazinamide. It becomes toxic to ''Mycobacterium tuberculosis'' when converted to pyrazinoic acid by the <scene name='Journal:JBSD:11/Cv/5'>bacterial pyrazinamidase (PncA) enzyme</scene>. PZA resistance is caused mainly by the loss of enzyme activity by mutation, the mechanism of resistance is not completely understood. In our studies, we analysed three mutations (D8G, S104R and C138Y) of PncA which are resistance for <scene name='Journal:JBSD:11/Cv/6'>PZA</scene>. Binding pocket analysis solvent accessibility analysis, molecular docking and interaction analysis were performed to understand the interaction behaviour of mutant enzymes with PZA. Molecular dynamics simulations were conducted to understand the three dimensional conformational behaviour of <scene name='Journal:JBSD:11/Cv/3'>native</scene> and mutants PncA. Our analysis clearly indicates that the mutation (<scene name='Journal:JBSD:11/Cv/8'>D8G</scene>, <scene name='Journal:JBSD:11/Cv/9'>S104R</scene> and <scene name='Journal:JBSD:11/Cv/10'>C138Y</scene>) in PncA is responsible for rigid binding cavity which in turns abolishes conversion of PZA to its active form and is the sole reason for PZA resistance. Excessive hydrogen bonding between PZA binding cavity residues and their neighboring residues are the reason of rigid binding cavity during simulation. We present an exhaustive analysis of the binding-site flexibility and its 3D conformations that may serve as new starting points for structure-based drug design and helps there researchers to design new inhibitor with consideration of rigid criterion of binding residues due to mutation of this essential target.
Tuberculosis continues to be a global health threat. Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis treatment. The emergence of strains resistant to pyrazinamide represents an important public health problem, as both first- and second-line treatment regimens include pyrazinamide. It becomes toxic to ''Mycobacterium tuberculosis'' when converted to pyrazinoic acid by the <scene name='Journal:JBSD:11/Cv/5'>bacterial pyrazinamidase (PncA) enzyme</scene>. PZA resistance is caused mainly by the loss of enzyme activity by mutation, the mechanism of resistance is not completely understood. In our studies, we analysed three mutations (D8G, S104R and C138Y) of PncA which are resistance for <scene name='Journal:JBSD:11/Cv/6'>PZA</scene>. Binding pocket analysis solvent accessibility analysis, molecular docking and interaction analysis were performed to understand the interaction behaviour of mutant enzymes with PZA. Molecular dynamics simulations were conducted to understand the three dimensional conformational behaviour of <scene name='Journal:JBSD:11/Cv/3'>native</scene> and mutants PncA. Our analysis clearly indicates that the mutation (<scene name='Journal:JBSD:11/Cv/8'>D8G</scene>, <scene name='Journal:JBSD:11/Cv/9'>S104R</scene> and <scene name='Journal:JBSD:11/Cv/10'>C138Y</scene>) in PncA is responsible for rigid binding cavity which in turns abolishes conversion of PZA to its active form and is the sole reason for PZA resistance. Excessive hydrogen bonding between PZA binding cavity residues and their neighboring residues are the reason of rigid binding cavity during simulation. We present an exhaustive analysis of the binding-site flexibility and its 3D conformations that may serve as new starting points for structure-based drug design and helps there researchers to design new inhibitor with consideration of rigid criterion of binding residues due to mutation of this essential target.
-
=== Enoyl-Acyl-Carrier Protein Reductase ===
+
=== Enoyl-Acyl-Carrier Protein Reductase <ref>PMID:19130456</ref>===
-
Enoyl-Acyl-Carrier Protein Reductase is a target of anti-bacterial drugs such as triclosan (TCL). These drugs are used against tuberculosis infection. <scene name='43/434541/Cv/10'>Enoyl-Acyl-Carrier Protein Reductase is a tetramer</scene>. InhA ENR <scene name='43/434541/Cv/11'>active site contains NAD and TCL</scene>.<ref>PMID:19130456</ref>
+
Enoyl-Acyl-Carrier Protein Reductase is a target of anti-bacterial drugs such as triclosan (TCL). These drugs are used against tuberculosis infection. <scene name='43/434541/Cv/10'>Enoyl-Acyl-Carrier Protein Reductase is a tetramer</scene> (PDB code [[3fne]]). InhA ENR <scene name='43/434541/Cv/11'>active site contains NAD and triclosan derivative</scene>.
</StructureSection>
</StructureSection>

Revision as of 12:33, 24 October 2019

Drag the structure with the mouse to rotate

References

  1. Lazo EO, Jakoncic J, RoyChowdhury S, Awasthi D, Ojima I. Novel T9 loop conformation of filamenting temperature-sensitive mutant Z from Mycobacterium tuberculosis. Acta Crystallogr F Struct Biol Commun. 2019 May 1;75(Pt 5):359-367. doi:, 10.1107/S2053230X19004618. Epub 2019 Apr 24. PMID:31045565 doi:http://dx.doi.org/10.1107/S2053230X19004618
  2. Ko TP, Xiao X, Guo RT, Huang JW, Liu W, Chen CC. Substrate-analogue complex structure of Mycobacterium tuberculosis decaprenyl diphosphate synthase. Acta Crystallogr F Struct Biol Commun. 2019 Apr 1;75(Pt 4):212-216. PMID:30950820 doi:10.1107/S2053230X19001213
  3. Gupta AK, Behera D, Gopal B. The crystal structure of Mycobacterium tuberculosis high-temperature requirement A protein reveals an autoregulatory mechanism. Acta Crystallogr F Struct Biol Commun. 2018 Dec 1;74(Pt 12):803-809. doi:, 10.1107/S2053230X18016217. Epub 2018 Nov 29. PMID:30511675 doi:http://dx.doi.org/10.1107/S2053230X18016217
  4. Hasenbein S, Meltzer M, Hauske P, Kaiser M, Huber R, Clausen T, Ehrmann M. Conversion of a regulatory into a degradative protease. J Mol Biol. 2010 Apr 9;397(4):957-66. doi: 10.1016/j.jmb.2010.02.027. Epub 2010, Feb 22. PMID:20184896 doi:http://dx.doi.org/10.1016/j.jmb.2010.02.027
  5. Sohn J, Grant RA, Sauer RT. OMP peptides activate the DegS stress-sensor protease by a relief of inhibition mechanism. Structure. 2009 Oct 14;17(10):1411-21. PMID:19836340 doi:10.1016/j.str.2009.07.017
  6. Ash EL, Sudmeier JL, Day RM, Vincent M, Torchilin EV, Haddad KC, Bradshaw EM, Sanford DG, Bachovchin WW. Unusual 1H NMR chemical shifts support (His) C(epsilon) 1...O==C H-bond: proposal for reaction-driven ring flip mechanism in serine protease catalysis. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10371-6. PMID:10984533
  7. Radisky ES, Lee JM, Lu CJ, Koshland DE Jr. Insights into the serine protease mechanism from atomic resolution structures of trypsin reaction intermediates. Proc Natl Acad Sci U S A. 2006 May 2;103(18):6835-40. Epub 2006 Apr 24. PMID:16636277
  8. Dym O, Albeck S, Peleg Y, Schwarz A, Shakked Z, Burstein Y, Zimhony O. Structure-function analysis of the acyl carrier protein synthase (AcpS) from Mycobacterium tuberculosis. J Mol Biol. 2009 Nov 6;393(4):937-50. Epub 2009 Sep 3. PMID:19733180 doi:10.1016/j.jmb.2009.08.065
  9. Rajendran V, Sethumadhavan R. Drug resistance mechanism of PncA in Mycobacterium tuberculosis. J Biomol Struct Dyn. 2013 Feb 6. PMID:23383724 doi:10.1080/07391102.2012.759885
  10. Freundlich JS, Wang F, Vilcheze C, Gulten G, Langley R, Schiehser GA, Jacobus DP, Jacobs WR Jr, Sacchettini JC. Triclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis. ChemMedChem. 2009 Jan 7. PMID:19130456 doi:10.1002/cmdc.200800261

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Personal tools